Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Slovenia

Sales Up For Lek

July 2006 | Company Finance Alert

Outperforming its competitors, Slovenia firm Lek - part of the generics division of Swiss company Sandoz - has released financial results for the first half of 2006 in which sales increased by an impressive 13% to SIT74.2bn

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles
Cost-Containment Measures For Pharmaceuticals On Top Of Further Healthcare Cuts

Industry / Slovenia In addition to a EUR49mn (US$61mn) reduction in its healthcare budget in early June, the Slovenian Ministry of Health has now proposed a series of pharmaceutical cost-containment measures. These developments...
July 2010
Lek Expands Biosimilar Production

Industry / Slovenia Slovenian pharmaceutical company Lek, a division of Novartis's generic arm Sandoz, has opened a new US$3.8mn biopharmaceutical production facility to produce biosimilar epoetin alfa. Sandoz markets epoetin...
March 2010
New Health Services Act To Improve Efficiencies

Industry / Slovenia The Slovenian government approved a draft Health Services Act in March 2010, laying the groundwork for system reform in the country. The act introduces a number of reforms that will reorganise the provision...
March 2010
Krka Eyeing Acquisitions

Companies / Slovenia Slovenian generic drugmaker Krka plans to continue its strong organic growth strategy during 2010, while also eyeing potential takeover opportunities. Chief Executive Jože Colarič told Reuters...
February 2010
Krka Opens API Plant

Companies / Slovenia Leading Slovenian drugmaker Krka has officially opened its Sinteza 4 active pharmaceutical ingredient (API) production facility. The EUR80mn (US$107mn) plant will allow the firm to manufacture most of...
June 2007
Emerging Europe InsightEmerging Europe Channels Emerging Europe Countries


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2012 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS